Pyxis Oncology, Inc. filings document a clinical-stage oncology company developing MICVO, an investigational antibody-drug conjugate for difficult-to-treat cancers. Its 8-K reports cover financial results, corporate updates, Regulation FD presentations, clinical data disclosures, and trial-related updates for MICVO in recurrent or metastatic head and neck squamous cell carcinoma and other advanced solid tumors.
The company’s regulatory record also includes proxy materials for annual meeting matters, director elections, governance proposals, executive transitions, employment and separation arrangements, equity compensation matters, and emerging growth company status. These filings describe Pyxis Oncology’s public-company governance, program disclosures, capital-related arrangements, and risk-linked clinical development reporting.
Pyxis Oncology, Inc. (PYXS) is the issuer in an amended Schedule 13G reporting that Laurion Capital Management LP, Benjamin Alexander Smith and Janaka Sheehan Maduraperuma each report beneficial ownership of 4,300,888 shares, or 5.16% of the common stock. The reported position carries shared voting and dispositive power; the three reports refer to the same shares, not separate positions to add together. The Laurion Funds directly hold the shares, and Laurion Capital Master Fund Ltd. has rights to dividends or sale proceeds associated with more than 5% of the class. The reporting persons state that the filing is not an admission of beneficial ownership for purposes of Section 13 of the Act.
Pyxis Oncology, Inc. (PYXS) is asking stockholders to approve an increase in authorized common stock from 190,000,000 to 380,000,000 shares. The vote is scheduled for November 13, 2026, and the board recommends voting for the amendment. As of October 8, 2026, 119,583,637 common shares were outstanding; 39,698,811 shares were reserved for outstanding options, restricted stock units and warrants, and 3,072,366 shares were reserved for future equity-plan awards.
Pyxis says it lacks enough authorized, unissued shares to permit exercise of common warrants for up to 49,310,352 shares, issued in connection with an offering that closed October 1, 2026. If stockholders approve the amendment, the company intends to use some of the added authorization to permit warrant exercise. If they do not, the warrants will not be exercisable and may have no value. Future share issuances could dilute earnings per share, book value per share and current stockholders’ voting power. A second proposal would allow adjournment to solicit additional votes if needed.
Pyxis Oncology (PYXS) is asking stockholders to approve an amendment increasing authorized common shares from 190,000,000 to 380,000,000, subject to stockholder approval. The special meeting is scheduled for November 13, 2026; holders of record on October 8, 2026 may vote.
As of October 8, 2026, 119,583,637 common shares were outstanding, with 39,698,811 reserved for outstanding options, restricted stock units and warrants and 3,072,366 reserved for future equity-plan awards. Pyxis says current authorization is insufficient for exercise of common warrants to purchase up to 49,310,352 shares; if approved, it intends to use part of the added authorization for that purpose. Future issuances could dilute per-share metrics and voting interests. The Board recommends voting FOR both proposals, including adjournment if needed to seek additional proxies.
For Pyxis Oncology, Inc. (PYXS), GordonMD Global Investments LP, GordonMD Long Biased Master Fund LP, GordonMD Long Biased GP LLC and Craig D. Gordon each report beneficial ownership of 20,441,948 shares, or 16.4%, with shared voting and dispositive power over that same reported position.
The reported amount includes 4,900,039 shares issuable upon warrant exercise. It excludes 7,172,000 shares issuable upon exercise of warrants only once stockholder approval is obtained, and then subject to a 17.50% beneficial ownership blocker. The securities are directly owned by advisory clients of GordonMD Global Investments LP; the report states that only the Master Fund may be deemed to beneficially own more than 5% among those clients. Each reporting person disclaims beneficial ownership except to the extent of pecuniary interest.
Pyxis Oncology, Inc. (PYXS) reports that GordonMD Long Biased Master Fund LP purchased 7,172,000 Common Stock Purchase Warrants on October 1, 2026, and reported a resulting position of 7,172,000 warrants; the Form 4/A corrects the warrant count in a report filed October 2, 2026. The warrants relate to 7,172,000 underlying common shares. Their exercise price is $3.50, subject to adjustment. The combined public offering price for each common share and accompanying warrant was $2.90. No Rule 10b5-1 plan is reported.
The warrants are held directly by the Master Fund, whose investment manager is GordonMD Global Investments LP. Craig D. Gordon is managing member of GordonMD Long Biased GP LLC, the Master Fund’s general partner. The warrants cannot be exercised until stockholders approve an amendment increasing authorized common shares and that amendment is filed and effective under Delaware law. The Master Fund, GP and Craig D. Gordon disclaim beneficial ownership for Section 16 purposes except to the extent of any pecuniary interest.
Pyxis Oncology, Inc. (PYXS) is the subject of a Schedule 13G in which Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC and Matthew D. Perry each report beneficial ownership of 6,448,907 common shares, or 5.42%. The shares are held directly by Coastlands Capital Partners LP, and each reporting person reports shared voting and dispositive power.
The reported percentage is calculated using 119,083,008 shares outstanding as of October 1, 2026. The reporting persons exclude pre-funded warrants and warrants held in excess of a 4.99% beneficial ownership limitation, and state that they filed jointly but not as members of a group.
GordonMD Long Biased Master Fund LP, a ten-percent owner of Pyxis Oncology, Inc. (PYXS), purchased 5,517,000 common shares and Common Stock Purchase Warrants covering 7,546,766 common shares on October 1, 2026. The combined public offering price for each common share and accompanying warrant was $2.90.
The Master Fund reported 15,541,909 common shares and 7,546,766 warrants after the transactions. The warrants have a $3.50 exercise price, subject to adjustments, and cannot be exercised unless stockholders approve an amendment increasing authorized common shares and the amendment is filed and becomes effective under Delaware law. The Master Fund directly holds the securities; GordonMD Global Investments LP is its investment manager. Craig D. Gordon is managing member of GordonMD Long Biased GP LLC; the Master Fund, GP and Mr. Gordon disclaim beneficial ownership except to the extent of any pecuniary interest. No Rule 10b5-1 plan is reported.
Pyxis Oncology, Inc. (PYXS) is the issuer in an amended Schedule 13G reporting a shared position of 27,988,714 common shares for each of four reporting persons: GordonMD Global Investments LP, GordonMD Long Biased Master Fund LP, GordonMD Long Biased GP LLC and Craig D. Gordon. The same amount is repeated across the reporting persons and does not represent four separate blocks.
The reported position includes 12,446,805 shares issuable upon full exercise of warrants, without giving effect to a 17.50% blocker. The reported ownership percentage is 17.5% and gives effect to the blocker; certain warrants are not presently exercisable where exercise would cause the reporting persons’ beneficial ownership to exceed 17.50%. The securities are directly owned by advisory clients of GordonMD Global Investments LP, and the reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest.
Pyxis Oncology, Inc. (PYXS) closed its underwritten public offering on October 1, 2026. It sold 36,047,919 common shares and pre-funded warrants for 1,883,121 shares, together with common warrants to purchase up to 49,310,352 shares. Each share or pre-funded warrant was sold with a common warrant for 1.3 shares; package prices were $2.90 and $2.899, respectively.
Net proceeds were approximately $102.8 million. Cash exercise of all warrants in full would provide approximately $162.2 million in additional proceeds, net of the 6% warrant exercise solicitation fee and before other applicable fees and expenses. Common warrants have a $3.50 per-share exercise price and require stockholder approval of a charter amendment increasing authorized common shares, and the amendment must be filed and become effective. Without these conditions, they may have no value. Pyxis intends to use proceeds for MICVO, including planned Phase 3 Headliner, working capital and general purposes; it expects existing cash plus proceeds to fund operating expenses and capital expenditures into the first half of 2028. Without warrant exercise, those funds will not fully fund the planned Phase 3 trial.
Pyxis Oncology, Inc. is offering 36,047,919 common shares, pre-funded warrants for 1,883,121 shares, and common warrants for 49,310,352 shares. Each common share or pre-funded warrant is paired with a warrant for 1.3 shares, at package prices of $2.900 and $2.899, respectively. Estimated net proceeds of approximately $102.8 million are intended for MICVO clinical milestones, including a planned Phase 3 trial, working capital and general corporate purposes.
The common warrants have a $3.50 exercise price and cannot be exercised until stockholders approve an authorized-share charter amendment and it becomes effective. PYXS expects existing cash plus proceeds to fund operating expenses and capital needs into the first half of 2028, based on assumptions; without warrant exercise, offering proceeds and existing cash will not fully fund the planned pivotal Phase 3 trial. Phase 1 data through August 18, 2026, in the 5.4 mg/kg dose-cap efficacy group (N=33), showed a 36% confirmed objective response rate (12/33), 94% disease control rate (31/33), median progression-free survival of 6.2 months and 79% 12-month overall survival probability. Grade 3-or-higher treatment-related adverse events occurred in 19 of 35 patients (54.3%); there were no treatment-related deaths.